Prostate cancer is not positively responsive to immunotherapy. The recent clinical trials conducted have hinted that when immunotherapy and radiation therapy are combined, they can be a powerful treatment approach for castration-resistant prostate cancer.
Androgen deprivation therapy is the current cornerstone of managing advanced hormone-sensitive prostate cancer. However, patients often enter into a castration-resistant stage where the tumor progresses despite undergoing androgen deprivation. Until recently, patients have been treated with chemotherapy.
Considering that today’s prostate cancer profiling has changed, more patients will be willing to embrace the new concepts in prostate cancer treatment. This clearly suggests that developing novel therapeutic agents or regimes that will target the broader spectrum of pathway components will greatly improve the clinical benefits of systematic therapy. Doctors and scientists have better recognition of risk assessment. And there is also a higher acceptance of multimodality treatment among patients, with great anticipation of novel therapeutics as new concepts emerge. With new ways to better risk-stratify patients, it is quite clear that multimodality therapy is the way to go.
0 Comments
|
AuthorAs the founder and medical director of the Prostate Seed Institute Dr. Gregory A. Echt. His vision to provide the most modern treatment, non surgical treatments for prostate cancer in various locations throughout the Dallas-Fort Worth continues to succeed. Now date, he has made a therapy for prostate implantation seed at over 2,500 men, including urologists and oncologists. Archives
December 2019
Categories |